Skip to main content
Premium Trial:

Request an Annual Quote

Quest Licenses HIV Tropism Assay from Pathway Diagnostics

NEW YORK (GenomeWeb News) — Quest Diagnostics has licensed from Pathway Diagnostics the underlying technology used in its co-receptor tropism HIV assay, Quest said today.
The non-exclusive license covers the heteroduplex tracking technology used in Pathway’s SensiTrop test. Quest said that a molecular-based assay for co-receptor tropism will help physicians personalize HIV therapy.
Quest, which is the first full-service national clinical laboratory in the US to license the technology, expects to develop a validated assay using the technology in the first quarter of 2008. Until then, the SensiTrop test may be ordered through Quest, which will refer the test to Pathway Diagnostics.
"HIV co-receptor tropism tests can help physicians identify which patients, of the estimated 500,000 people in the US being treated for HIV infection, will benefit from entry inhibitor drugs, the latest development in life-enhancing anti-retroviral therapies,” Joyce Schwartz, Quest’s vice president and chief laboratory officer, said in a statement.
Financial terms of the agreement were not released.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.